CTOR (Citius Oncology) Effective Interest Rate on Debt %: 3.47% (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Effective Interest Rate on Debt %?

Citius Oncology CTOR -2.10% 10 Effective Interest Rate on Debt % is 3.47% as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Citius Oncology's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.13 Mil. Citius Oncology's average total debt for the quarter that ended in Mar. 2026 was $3.80 Mil. Therefore, Citius Oncology's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was 3.47%.

Citius Oncology  (NAS:CTOR) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Citius Oncology Effective Interest Rate on Debt % Related Terms

Citius Oncology Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Effective Interest Rate on Debt % Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Effective Interest Rate on Debt %
0.00 0.00 0.00 5.74

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 16.95 6.00 4.84 3.47

CTOR vs INCR, TLPH, ETST: Effective Interest Rate on Debt % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology Effective Interest Rate on Debt % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Effective Interest Rate on Debt % falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Effective Interest Rate on Debt % Calculation

Citius Oncology's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Sep. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Sep. 2024 )+Total Debt  (A: Sep. 2025 ))/ count )
=-1  *  -0.218/( (3.8+3.8)/ 2 )
=-1  *  -0.218/3.8
=5.74 %

where

Total Debt  (A: Sep. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.8 + 0
=3.8

Total Debt  (A: Sep. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.8 + 0
=3.8

Citius Oncology's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2025 )+Total Debt  (Q: Mar. 2026 ))/ count )
=-1  *  -0.132/( (3.8+3.8)/ 2 )
=-1  *  -0.132/3.8
=3.47 %

where

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.8 + 0
=3.8

Total Debt  (Q: Mar. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.8 + 0
=3.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 3.47% mean?
Citius Oncology (CTOR) has a Effective Interest Rate on Debt % of 3.47% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's Effective Interest Rate on Debt % too high?
Citius Oncology's current Effective Interest Rate on Debt % is 3.47%. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Effective Interest Rate on Debt % compare to INCR and TLPH?
Citius Oncology's Effective Interest Rate on Debt % of 3.47% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Drug Manufacturers company?
A good Effective Interest Rate on Debt % depends on the Drug Manufacturers industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Citius Oncology and its competitors. Citius Oncology's current Effective Interest Rate on Debt % is 3.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Effective Interest Rate on Debt % of 3.47%. The current Effective Interest Rate on Debt % is 3.47%. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Effective Interest Rate on Debt % is 3.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price